- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1950
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Risankizumab: A Review in Moderate to Severe Plaque Psoriasis ; volume:80 ; number:12 ; day:6 ; month:7 ; year:2020 ; pages:1235-1245 ; date:8.2020
Drugs ; 80, Heft 12 (6.7.2020), 1235-1245, 8.2020
- Creator
-
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-020-01357-1
- URN
-
urn:nbn:de:101:1-2020111320202243747377
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
Ixekizumab for Treating Moderate-to-Severe Plaque Psoriasis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Correction to: Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
Correction to: Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
Oral microbiota diversity in moderate to severe plaque psoriasis, nail psoriasis and psoriatic arthritis
Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective
Cost of Moderate to Severe Plaque Psoriasis in Germany: A Multicenter Cost-of-Illness Study
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis
A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis